(S)-Ibuprofen

(S)-Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) and a COX-1 and COX-2 inhibitor (IC₅₀s = 2.6 and 1.53 µM, respectively).¹ It inhibits NF-κB transactivation in a reporter assay using Jurkat T cells (IC₅₀ = 61.7 µM).² (S)-Ibuprofen reduces aggregation in platelet-rich plasma and washed isolated human platelets (IC₅₀s = 88 and 0.6 µM, respectively).³ It decreases superoxide formation and β-glucuronidase release induced by N-formyl-Met-Leu-Phe (fMLP; Item No. 21495), as well as leukotriene B₄ (LTB₄; Item No. 20110) formation induced by calcimycin (A23187; Item No. 11016), in human polymorphonuclear (PMN) cells (IC₅₀s = 0.50, 0.53, and 0.14 µM, respectively). (S)-Ibuprofen increases the latency to withdrawal in hot plate and tail-flick tests in mice (ED₅₀s = 64 and 54 mg/kg, respectively), as well as reduces paw swelling in a mouse model of carrageenan-induced paw edema (ED₅₀ = 57 mg/kg).⁴ Formulations containing (±)-ibuprofen have been used in the treatment of fever and mild-to-severe pain.

WARNING This product is not for human or veterinary use.

1. Barnett, J., Chow, J., Ives, D., et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta 1209(1), 130-139 (1994).

2. Scheuren, N., Bang, H., Münster, T., et al. Modulation of transcription factor NF-κB by enantiomers of the nonsteroidal drug ibuprofen. Br. J. Pharmacol. 123(4), 645-652 (1998).

3. Villanueva, M., Heckenberger, R., Strobach, H., et al. Equipotent inhibition by R(−)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br. J. Clin. Pharmacol. 35(3), 235-242 (1993).

4. Bonabello, A., Galmozzi, M.R., Canaparo, R., et al. Dexibuprofen (S+-isomer ibuprofen) reduces gastric damage and improves analgesic and antiinflammatory effects in rodents. Anesth. Analg. 97(2), 402-408 (2003).